Helix BioMedix, Inc.

HXBM

US4232875074

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 14:31:09 07/02/2024 GMT			5-day change	1st Jan Change
23.27 ^USD	-.--%		-.--%	-.--%

2022	Thai, Vietnam rice price hike plan 'impossible', Thai export body says	RE
2019	Helix Biomedix Raises USD 5.62 Million in Debt Funding	CI

Helix Biomedix Raises USD 5.62 Million in Debt Funding

August 31, 2019

Helix Biomedix has raised USD 5.62 million in debt funding through private placement. Deal status: Completed on July 29, 2019.

Latest news about Helix BioMedix, Inc.

Thai, Vietnam rice price hike plan 'impossible', Thai export body says	30/05/22	RE
Helix Biomedix Raises USD 5.62 Million in Debt Funding	31/07/19	CI
Helix BioMedix, Inc. announced that it has received $5.62512 million in funding	29/07/19	CI
Helix BioMedix, Inc. announced that it expects to receive $5.62512 million in funding	14/07/19	CI
Helix BioMedix, Inc. Announces Executive Changes	10/07/17	CI
Helix Biomedix Inc. announced that it has received $1 million in funding	02/12/14	CI
Helix Biomedix Inc. announced that it expects to receive $4.5 million in funding.	17/11/14	CI
Helix Biomedix Inc. announced that it expects to receive $4.5 million in funding.	18/04/13	CI
Helix Biomedix Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2012	09/11/12	CI
Helix Biomedix Inc. Reports Unaudited Earnings Results for the Second Quarter and Half Year Ended June 30, 2012; Launches New Apothederm(TM) Acne Clarifying Treatment	03/08/12	CI
Helix Biomedix Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2012	11/05/12	CI
Helix Biomedix Inc. Announces Unaudited Earnings Results for the Year Ended December 31, 2011	28/03/12	CI

Helix BioMedix, Inc. is a peptide discovery and development biopharmaceutical company, which is focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum. The Companyâs lead drug development candidate, HB4208, is a deoxyribonucleic damage response enzyme for topical treatment of the rare genetic disorder (orphan disease) Xeroderma Pigmentosum (XP). Its intellectual property portfolio offers multiple pathways for commercialization in this area ranging from Rx dermatology to aesthetic dermatology and personal care. It is developing new treatment options for dermatologic conditions which offer the therapeutic effectiveness and safety benefits of its advanced bioactive small molecule technology. It is transforming the treatment of skin conditions by addressing unmet needs in elegant, life-enhancing topical formulations. Its research and development consist of a proprietary library of bioactive peptides based on the bodyâs innate immunity.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HELIX BIOMEDIX, INC.	-.--%	5.23M
MODERNA, INC.	+26.37%	44.96B
IQVIA HOLDINGS INC.	-1.01%	42.65B
LONZA GROUP AG	+46.00%	41.85B
CELLTRION, INC.	-5.31%	29.04B
ICON PUBLIC LIMITED COMPANY	+9.34%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.69%	19.03B
BIO-TECHNE CORPORATION	+6.23%	12.75B
MEDPACE HOLDINGS, INC.	+26.99%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.38%	11.75B

Other Biotechnology & Medical Research

Helix BioMedix, Inc.

Equities

HXBM

US4232875074

Biotechnology & Medical Research

Helix Biomedix Raises USD 5.62 Million in Debt Funding

Latest news about Helix BioMedix, Inc.

Chart Helix BioMedix, Inc.

Company Profile

Sector Other Biotechnology & Medical Research